Get the Stockscreener App
34.80
50.42%
-35.39
Pre-market:
35.96
1.16
+3.33%
Corcept Therapeutics Inc stock is traded at $34.80, with a volume of 20.27M.
It is down -50.42% in the last 24 hours and down -56.17% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
See More
Previous Close:
$70.19
Open:
$38.89
24h Volume:
20.27M
Relative Volume:
17.48
Market Cap:
$3.66B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
27.62
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
-58.37%
1M Performance:
-56.17%
6M Performance:
-52.59%
1Y Performance:
-30.94%
1-Day Range:
$32.99
$39.00
1-Week Range:
$32.99
$83.70
52-Week Range:
$32.99
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
34.80 | 7.38B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | UBS | Neutral |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
US FDA declines to approve Corcept's drug for rare hormonal disorder - Reuters
Kaplan Fox Announces an Investigation Into Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations - The National Law Review
Corcept Therapeutics stock tanks on FDA relacorilant setback — what happens next for CORT - ts2.tech
Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets - ts2.tech
A Risky Spot For Corcept Therapeutics (NASDAQ:CORT) - Seeking Alpha
What drives Corcept Therapeutics Incorporated stock priceTrading Psychology Tips & Build Wealth With Strategy - earlytimes.in
FDA says it needs additional evidence of effectiveness for Corcept relacorilant - Yahoo Finance
Stocks making big moves yesterday: FuelCell Energy, Corcept, and PacBio - TradingView — Track All Markets
The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56% - simplywall.st
Why We're Not Concerned Yet About Corcept Therapeutics Incorporated's (NASDAQ:CORT) 56% Share Price Plunge - 富途牛牛
Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT - ts2.tech
Why Corcept Therapeutics plummeted by 50% today - MSN
Why Corcept Therapeutics Plummeted by 50% Today - The Globe and Mail
Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension - ts2.tech
Why Corcept Therapeutics Plummeted by 50% Today - The Motley Fool
Why Corcept (CORT) Shares Are Falling Today - Finviz
Why Corcept Therapeutics stock crashed today and what comes next? - CryptoRank
Corcept stumbles after Cushing's drug met with FDA rebuff - FirstWord Pharma
Kaplan Fox & Kilsheimer LLP is Investigating Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations - NewMediaWire
Corcept Therapeutics price target lowered to $50 from $135 at Truist - TipRanks
Corcept Therapeutics Faces FDA Setback for Relacorilant Approval - TipRanks
Corcept Therapeutics Inc Receives FDA Complete Response Letter for Relacorilant - TradingView — Track All Markets
Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next - ts2.tech
Stock Traders Buy Large Volume of Put Options on Corcept Therapeutics (NASDAQ:CORT) - MarketBeat
Truist Securities Lowers Corcept Therapeutics' Price Target to $50 From $135, Buy Rating Kept - marketscreener.com
Truist Securities lowers Corcept Therapeutics stock price target on FDA concerns - Investing.com Nigeria
US FDA declines to approve Corcept’s drug for rare hormonal disorder - WTAQ
Corcept nosedives 48% after FDA rejected core drug - breakingthenews.net
Nasdaq Moves Lower; US Crude Oil Inventories Decline Sharply - Benzinga
Nvidia, Tesla, Nike, DJT, Hecla, Newmont, Corcept, Vanda, and More Market Movers - Barron's
Corcept Therapeutics (CORT) Sees Significant Decline in Stock Va - GuruFocus
Corcept Therapeutics Stock (CORT) Opinions on FDA Rejection of Relacorilant - Quiver Quantitative
Corcept Therapeutics Shares Drop 50% After FDA Rejects Drug - Barron's
Stocks making the biggest moves midday: Nike, Corcept Therapeutics, Taiwan Semiconductor & more - CNBC
Corcept looks to ovarian cancer as relacorilant gets CRL in Cushing - BioWorld MedTech
Corcept Therapeutics (NASDAQ:CORT) Sets New 12-Month Low After Analyst Downgrade - MarketBeat
Nvidia, Tesla, Hecla, Newmont, Nike, Vanda, Corcept, DJT, and More Market Movers - Barron's
Wolfe Research Downgrades Corcept Therapeutics to Underperform from Peer Perform, Price Target is $30 - marketscreener.com
Wolfe Research downgrades Corcept Therapeutics stock rating to Underperform By Investing.com - Investing.com UK
Corcept Therapeutics (CORT) Stock Plummets Over 48% - GuruFocus
FDA rejects Corcept’s cortisol-targeting drug for Cushing’s syndrome - Endpoints News
Wolfe Research Downgrades Corcept Therapeutics (NASDAQ:CORT) to Underperform - MarketBeat
Corcept Shares Sink After FDA Rejects Drug to Treat Hypertension - Bloomberg.com
Corcept Therapeutics stock hits 52-week low at $38.78 - Investing.com
Corcept Therapeutics (CORT) Shares Plummet After FDA Rejects Dru - GuruFocus
Why Is Corcept Therapeutics Stock Sinking Wednesday?Corcept Therapeutics (NASDAQ:CORT) - Benzinga
Dow Falls 50 Points; US Initial Jobless Claims Decline - Benzinga
Corcept Therapeutics (CORT) Shares Plummet After FDA Setback - GuruFocus
FDA rejects Peninsula company's rare disease drug, sending stock to $4 billion-plus selloff - The Business Journals
Corcept Therapeutics stock hits 52-week low at $38.78 By Investing.com - Investing.com UK
Corcept Therapeutics (CORT) Shares Plummet After FDA Rejects Drug - GuruFocus
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):